Trials / Recruiting
RecruitingNCT06511882
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Who Have Achieved Negative Measurable Residual Disease (MRD)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azacitidine | Standard of Care Intravenous (IV) infusion |
| DRUG | Decitabine | Standard of Care Intravenous (IV) infusion |
| DRUG | Venetoclax | Standard of Care PO (By Mouth) |
Timeline
- Start date
- 2024-11-07
- Primary completion
- 2027-10-01
- Completion
- 2028-08-01
- First posted
- 2024-07-22
- Last updated
- 2026-02-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06511882. Inclusion in this directory is not an endorsement.